Johnson & Johnson's Revolutionary Hemostatic Innovation SURGICEL® Powder Receives NMPA Approval via Fast-Track Review

China's Medical Device Innovation Green Channel Accelerates Innovative Products for Patient Benefit

Shanghai, August 22, 2022 /PR Newswire/ -- Recently, Johnson & Johnson Medical Technology has made a new breakthrough in accelerating the introduction of innovative products. Through the National Medical Device Innovation Green Channel, its world-leading hemostatic product...SURGICEL^®(Surgicel) Agglomerated ParticlesApproved by the National Medical Products Administration, becoming the first granular regenerated oxidized cellulose hemostatic product in China,Can be used in various types of surgical procedures., with its unique granular structure enhancing intraoperative hemostasis efficiency, innovatively empowers surgical procedures to be more reassuring and efficient, benefiting patients.

SURGICEL® (Surgicel) Aggregation Particles Approved via China's Medical Device Innovation Green Channel

Senior Director of Johnson & Johnson Medical Technology's Ethicon Biosurgery Division, Chen Songxin, stated:"Hemostasis is one of the three cornerstones of surgery. We continuously accelerate the introduction of innovative hemostatic products in various forms and properties, constantly improving surgical quality and patient safety. This year, we are honored to have achieved rapid approval for a new product with revolutionary innovative technology on China's 'fast track' for encouraging medical device innovation. We are proud of SURGICEL."^®(Surgicel) Accumulated particles accelerate to serve patients in China with great enthusiasm."

As a revolutionary newcomer in the SURGICEL hemostasis family, Polygan has won numerous international and domestic awards, including the 2022 Society for Biomaterials Technological Innovation and Development Award, the 2021 Edison Patent Award, the 2018 20th MDEA Medical Design Excellence Award, the Global Top 100 R&D Technology Award, and the Global Design Excellence and Innovation Award.

"Since the launch of the first piece of Surgicel absorbable regenerated oxidized cellulose in 1961, for more than 60 years, we have been continuously innovating and conducting research and development, committed to empowering surgeons with better medical technology and serving patients."Global Chief Scientist of Ethicon Biosurgery, Johnson & Johnson Medical TechnologiesDr. Allen Y. Wang stated，"SURGICEL^®(The revolutionary granular structure of QuikClot Accumulation Granules was inspired by my experience of eating hash browns near the headquarters of Johnson & Johnson. The shape of the hash browns inspired me to innovate our hemostatic products using tightly packed, randomly shaped particles.)

Innovative Agglomerated Particle Structure Inspired by the Shape of Hash Browns

In the field of biosurgery, Johnson & Johnson Medical Technologies continues to improve and expand its biosurgery product line, committed to providing comprehensive solutions for hemostasis, anti-adhesion, and sealing in surgical procedures, helping to enhance surgical quality and patient safety. In March this year, another hemostatic product from its portfolio received approval for a new indication for dural closure, filling the gap for such products in preventing cerebrospinal fluid leakage in neurosurgery in China, and becoming a new blessing for patients undergoing brain surgery. This time, SURGICEL^®(Surgicel) Accumulated Granules Approved, Becoming Another New Milestone in the Company's Accelerated Innovation in the Biosurgery Field.

As a global leader in the healthcare industry, Johnson & Johnson is guided by its credo to promote and improve human health through innovative medical solutions. Over the past three decades in China, Johnson & Johnson’s medical technology business has continuously accelerated the introduction of globally leading innovative medical technologies and products, serving Chinese patients faster and better, igniting hope for life, improving quality of life, and supporting "Healthy China."